Tucuvi’s entry into Microsoft’s startup program gives its patient-care AI platform access to commercial channels, while the announcement discloses no new customer commitment or measured clinical result.
Tucuvi said Thursday, Oct. 15, that it had joined Microsoft for Startups’ Pegasus Program. Microsoft describes Pegasus as invite-only and lists sales-channel access, go-to-market support, technical resources and priority access to Azure AI among its general benefits. Tucuvi said the program is intended to help it reach more health systems.
Microsoft Marketplace lists Tucuvi Health Manager, published by Tucuvi Care, and identifies LOLA® as its patient-facing voice AI. Tucuvi says LOLA handles inbound and outbound calls, follows configurable clinical and administrative protocols, gathers structured information and escalates cases that need human attention. The company says the platform integrates with Microsoft Foundry and Azure Speech.
Tucuvi says the platform covers more than 50 workflow types. Its examples include post-discharge follow-up, chronic-care monitoring, care-gap closure, medication adherence, prescription refills and scheduling. In July 2025, Tucuvi said its clinical voice AI had received Class IIb certification under the EU Medical Device Regulation.
Tucuvi says health systems and life-sciences companies can buy the platform through Microsoft Marketplace, and qualifying purchases may count against an existing Azure commitment. Microsoft’s guidance limits that benefit to Azure benefit-eligible offers purchased through the Azure portal.
Tucuvi CEO and co-founder María González Manso said the central issue for patient-facing AI is “who defines the protocol.” The announcement did not name a customer newly signed through Pegasus, provide a contract value or rollout schedule, or report measured patient results.
